Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients
Information source: Bayer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetic Nephropathies; Hypertension
Intervention: Adalat XL (Drug); Tiazac XC (Drug)
Phase: Phase 3
Sponsored by: Bayer
Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer
The study consists of a 12 week run-in period when all subjects are stabilized on a single
dose of Avalide (300 mg/12. 5 mg or 300mg/25mg dose) per day. After this 12 week run-in ends,
subjects will be randomly assigned to start the addition of either Adalat XL or Tiazac XC
for 18 weeks of treatment. Subjects will have a 1 in 2 chance of receiving the study drug
Adalat XL and a 1 in 2 chance of receiving the drug Tiazac XC. An end of treatment visit
will be done 18 weeks after start of study drug. The expected duration of the study is 30
weeks. The purpose of this study is to compare the change in proteinuria, through a urine
test, while taking study drug until high blood pressure (BP) is reduced to near normal
levels in study subjects with diabetic nephropathy and hypertension.
Official title: Randomized Open-label 2-arm Parallel Design Comparator Study of the Effect of Adalat® XL® Compared to Diltiazem on Proteinuria and Blood Pressure in Patients With Diabetes and Mild to Moderate Hypertension When Used as an Add on to Avalide®
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Change in Proteinuria
Percentage of subjects reaching a BP target of 130/80 mmHg at Week 18
Number and doses of anti-hypertensives used in the 2 treatment arms
Levels of urinary albumin and protein content and estimated glomerular filtration rate (GFR) in the 2 treatment groups
Early BP reduction from randomization achieved with the starting dose in the 2 treatment arms
Adverse Events leading to early withdrawal
All Adverse Events especially, edema
Change in index of glycemia (HbA1c)
Minimum age: 18 Years.
Maximum age: 80 Years.
- >/= 18 and < 80 years old.
- Diagnosed with hypertension.
- Diagnosed with diabetes mellitus type 2 for at least 6 mths prior to entry and on
stable medication for diabetes for at 1 mth prior to screening.
- Treated on ARB, ACE inhibitor with or without hydrochlorothiazide and suitable to
receive combination therapy with Avalide at 300mg/12. 5mg per day or 300mg/25mg per
- Diagnosed with diabetic nephropathy and have proteinuria between 0. 8g/day and
5. 0g/day at screening and then between 0. 8g/day and 3. 0g/day at randomization.
- Medically appropriate to receive Adalat XL or Tiazac XC.
- History of alcohol or substance abuse.
- Significant CV disorder such as ischemic heart disease, arrhythmias within the last 6
mths, or any history of severe congestive heart failure.
- Myocarditis or pericarditis within last 30 day of screening.
- ECG showing evidence of major arrhythmia or conduction disturbances requiring
treatment with anti-arrhythmic medication.
- Females with child-bearing potential or males with a partner of child-bearing
potential unless willing to use effective contraception during the study and 3 mths
after the end of study.
- Females who are pregnant, lactating or planning pregnancy during the study and for 3
mths after the study end.
- Known hypersensitivity to Adalat XL or Tiazac XC or other calcium channel blockers of
the dihydropyridine class.
- Resting heart rate <50 or >110 bpm.
- Presence of secondary or malignant hypertension.
- DBP >/= 180 and/or SBP >/= 110 mmHg.
Locations and Contacts
Click here and search for drug information provided by the FDA.
Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
Starting date: November 2008
Last updated: November 14, 2012